Position in CELC
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$9,335,661
+$8,632,395 QoQ
Shares Held
89,234
+1165.6% QoQ
Ownership
0.182%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
#72
of 274 holders
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Jefferies Financial Group Inc. holds $677,219,224 across 66 Biotechnology names. CELC ranks #15 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
1,357,042 | $110,693,915 | |
| 2 | URGN |
UroGen Pharma Ltd.
|
2,199,652 | $80,947,193 | |
| 3 | IMTX |
Immatics N.V.
|
6,506,802 | $65,913,904 | |
| 4 | TNGX |
Tango Therapeutics, Inc.
|
2,010,534 | $62,849,292 | |
| 5 | CGON |
CG Oncology, Inc.
|
769,947 | $54,704,734 | |
| 6 | ARGX |
Argenx SE
|
45,068 | $41,812,738 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
929,626 | $31,040,212 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
466,258 | $26,679,282 |
All Filings in CELC
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $9,335,661 | 89,234 | Shares | Defined | 2026-08-17 | |
| 2025-12-31 | $703,266 | 7,051 | Shares | Defined | 2026-02-09 | |
| No filing history on record for this holder in this stock. | ||||||